Recruits wanted for research into treatment for ‘broken heart syndrome’

Researchers at the University of Aberdeen are examining takotsubo cardiomyopathy.

Researchers at Aberdeen University are to trial the first ever treatment for takotsubo cardiomyopathy – nown as broken heart syndrome. (Hannah McKay/PA)
Researchers at Aberdeen University are to trial the first ever treatment for takotsubo cardiomyopathy – nown as broken heart syndrome. (Hannah McKay/PA)

Scientists hope to recruit almost 100 Scots for a trial of the first ever treatment for a condition known as broken heart syndrome.

Researchers at the University of Aberdeen are working on how to help those with takotsubo cardiomyopathy – a condition which affects around 5,000 people across the UK every year.

At least 7% of all heart attacks are attributed to the condition, where the heart muscle becomes suddenly weakened, usually because of severe emotional or physical stress.

Scientists will trial a programme of exercise and psychological therapies for those affected, with the work – described as a “huge step towards developing a standardised treatment” – taking place thanks to a grant of £300,000 from the British Heart Foundation

These trials to find the first ever treatment for the condition are a huge step forward

Professor James Leiper, British Heart Foundation

The university has already led the way on research into the condition, which was only recognised in the late 1990s.

The new trial aims to recruit 90 people from across Scotland, with participants signed up within three weeks of suffering an episode.

They will then be given either a personalised exercise conditioning programme, a regime of cognitive behavioural therapy, or be part of the control group.

The research is set to last for the next three years.

Dr David Gamble, from the University of Aberdeen, said: “Takotsubo cardiomyopathy, or broken heart syndrome, remains a comparatively poorly understood condition.

“It is vital that we develop a high-quality evidence base to guide clinicians in the management of this condition.

“In many clinical intervention trials, we are attempting to make incremental improvements to existing treatments, but as broken heart syndrome is at such an early stage there is no established treatment to use as a base.”

Professor Dana Dawson, also from the university, said: “We already know that cardiovascular disease affects men and women in different ways, so there is no reason why a one-size-fits-all treatment should work for broken heart syndrome.

“After so long spent researching this condition, it is great to be taking this huge step towards developing a standardised treatment for it and we look forward to seeing the results in due course.”

Professor James Leiper, associate medical director at the British Heart Foundation, said: “Takotsubo syndrome is a sudden and potentially catastrophic heart condition which has only been recognised in recent years.

“As such, these trials to find the first ever treatment for the condition are a huge step forward and will play a significant role in increasing our understanding of this neglected area of cardiology.”

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in